cell process – MD Update

A Paradigm-Shifting Discovery

June 1, 2012 Jennifer S. Newton achieve chimerism, biopsy, bone, bone marrow, breakthrough study co-authored, cell process, cellular therapeutics, chimerism, diabetes, director of the institute of cellular therapeutics, disorder, donor, donor chimerism, Dr. Suzanne, Dr. Suzanne T., dual immune system, engraftment, engraftment syndrome, facilitate cell, FDA, FDA-approved phase 2, FDA-approved phase 2 study, genetic source, graft, graft tolerance, harmful cell, hematopoietic, hematopoietic stem cell, high level of donor chimerism, high volume of kidney transplant, host disease, ICT, ICT lab, Ildstad, immunosuppressant, immunosuppressant drug regimen, immunosuppressant drug therapy, immunosuppression, Joseph Leventhal, kidney, kidney transplant, kidney transplant patient, kidney transplant recipient, Louisville, Louisville decade, Louisville researcher, marrow, mismatched patient, MLR, mobilization power, mobilization power of hematopoietic stem cell, multi-faceted power, multi-faceted power of stem cell, one, one year post-transplant, Paradigm-Shifting discovery, post-transplant, principal investigator of the study, protocol, published breakthrough study co-authored, recipient, regimen, researcher, simultaneous approach, singular organism, stem, stem cell, Suzanne T., T, therapeutics, tolerance, Translational Medicine1, transplant, transplantation, transplants2, type 1, type 1 diabetes, UofL, UofL researcher, white count

LOUISVILLE Decades in the making, a recently published breakthrough study co-authored by UofL researcher, Suzanne T. Ildstad, MD, demonstrates success